Sterling Financial Planning Inc. boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 47.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,295 shares of the company's stock after buying an additional 3,966 shares during the quarter. Sterling Financial Planning Inc.'s holdings in Johnson & Johnson were worth $2,039,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Checchi Capital Advisers LLC grew its stake in Johnson & Johnson by 2.1% in the first quarter. Checchi Capital Advisers LLC now owns 30,837 shares of the company's stock valued at $5,114,000 after purchasing an additional 631 shares in the last quarter. North Capital Inc. bought a new position in Johnson & Johnson in the first quarter valued at approximately $242,000. Summit Place Financial Advisors LLC boosted its stake in shares of Johnson & Johnson by 4.4% during the 1st quarter. Summit Place Financial Advisors LLC now owns 19,048 shares of the company's stock worth $3,159,000 after acquiring an additional 800 shares during the period. Rosenberg Matthew Hamilton boosted its stake in shares of Johnson & Johnson by 5.2% during the 1st quarter. Rosenberg Matthew Hamilton now owns 2,989 shares of the company's stock worth $496,000 after acquiring an additional 147 shares during the period. Finally, ZWJ Investment Counsel Inc. boosted its stake in shares of Johnson & Johnson by 1.4% during the 1st quarter. ZWJ Investment Counsel Inc. now owns 211,708 shares of the company's stock worth $35,110,000 after acquiring an additional 2,851 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Raymond James Financial reduced their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
JNJ traded up $0.34 during mid-day trading on Friday, reaching $155.90. 3,482,521 shares of the company traded hands, compared to its average volume of 8,059,757. The stock has a market capitalization of $375.11 billion, a P/E ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company's fifty day moving average price is $153.68 and its 200-day moving average price is $154.09. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
